

7th Framework Programme The Health Theme

Human Development and Ageing research



Patrik KOLAR Head of Unit Genomics and Systems Biology Health Directorate DG Research – European Commission

COOPERATION



Main points

The 7th Framework Programme (FP7)

- The Health Theme
- Submission and Evaluation
- > Outcome of calls 1 & 2
- Current and future calls
- > Ageing research in FP7
- > Additional funding sources
- Contacts & Information
- > Joint Programming





Collaborative Research in the Health Theme

Main policy drivers:

- Improving health of European citizens
- Increasing competitiveness of European health-related industries and businesses, with focus on research-intensive SMEs
- Addressing global health issues, including emerging epidemics





Scientific excellence at European level

From policy to funding the best research projects:

- The policy for Health research is described in the FP7 specific programme (available on CORDIS)
- Each year, a work programme is prepared by the EC, with the Advisory Group and in consultation with the Programme Committee
- Through calls for proposals the EC invites researchers from all Europe and beyond to submit their proposals
- The very best projects are selected on the basis of evaluation by independent experts (peer review)
- After negotiation of a grant agreement, a project is funded for 2-5 y.






Submission & evaluation

Basic principles:

- > annual calls single-stage or two-stage
- eligibility check (partners, limits, scope, deadline)
- > evaluation by panels of independent experts
 - overseen by Independent Observers
- > 3 criteria: Thresholds:
 - Science & Technology excellence 3/5
 - Implementation & Management 3/5 overall
 - Potential Impact3/510/15
- feedback: Evaluation Summary Reports (ESR







7

The Health theme structure and content

2: Translating research for human health

- Integrating biological data and processes: large-scale data gathering, systems biology
- Research on the brain and related diseases, <u>human development and ageing</u>
- Translational research in major infectious diseases

to confront major threats to public health antimicrobial drug resistance, HIV/AIDS, malaria and TB, emerging epidemics, neglected infectious diseases

Translational research in other major diseases: cancer, cardiovascular disease, diabetes and obesity, rare diseases, and other chronic diseases



The Health theme structure and content

- 3: Optimising the delivery of health care to citizens
- Translating clinical research into clinical practice patient safety, better use of medicines, benchmarking, pharmacovigilance, etc.
- Quality, efficiency and solidarity of health care systems organisational and financial aspects, health systems, etc.
- Enhanced health promotion and disease
 prevention providing evidence of best public health measures – life styles, interventions, special focus on mental health, etc.





9

Key figures from 1st 2 calls in FP7 Health Theme

<u>call: 2007-A (19/04/2007)</u>	<u>call: 2007-B</u>
<u>(18/09/2007)</u>	
Budget: \in 635 million (2007)	€ 567 million (2008)
Proposals received: 914	902
Proposals evaluated: 893 (ineligible	e 21) 865 (37)
Proposals funded: 153	172
(% of the proposals evaluated) : 1	6.7% 19%
Average grant per	
participant : €412.000	€334.000
SMEs in 100/152 projects (65.7%)	102/167 (60.7%)
210 SMEs involved (13.5%)	207 (11.9%)
Contribution to SMEs : €64.5 m	illion ~€70.5 million
11% of the budget	Objective: 15%



3rd call for proposals for the Health theme

The 3rd call has been published 03/09/2008

- by drawing on the budget for 2009: ~€ 593m*
- > there are in fact be two calls, published in parallel:
 - > `FP7-HEALTH-2009-single-stage' €476 m for most areas of the work programme deadline: 03/12/2008

> `FP7-HEALTH-2009-two-stage' €115 m only for areas 1.1 & 2.1. deadlines: 03/12/2008 for 1st stage 2nd stage: deadline in April 2009

(* including €2m for a topic via the ERA-NET call 2009)





HEALTH-2009-3.3.3: Ageing cohorts, single stage

Undertake multidisciplinary cohort work addressing the health of two ageing population groups, one group of ~50 to 70 years of age, and one group of ~65 to 85 years of age, to focus on developing robust health-related data at the EU level over a substantial time period - ~15 years. Such research should build on and complement work to-date (such as the European SHARE data set) to empower researchers and policy makers in various domains (healthcare, social care, pension provision) to take informed decisions. EU Member States should be covered and relevant European Commission services (Directorate-General for Health and Consumer protection, Directorate-General for Employment, Social Affairs and Equal Opportunities) and EUROSTAT be consulted.

Funding scheme:

Collaborative Project (Large-scale integrating project).



Next call for proposals for Human Development and Ageing

- The 4th call will be published probably end July 2009
- > there will be two calls, published in parallel:

> `single-stage' AND `two-stage'

- Both Human Development AND Ageing will be covered
- early development and longevity
- senescence
- frailty
- > development and lifespan





Funding schemes in the Health theme

Funding schemes	upper	' limits	min.	partners
Large-scale integrating project	ct (CP-	IP)*	€12m	≥3
Network of Excellence (NoE)		€12m	≥:	3
Small- or medium-scale focus	sed			
research project (CP-FP)	€3	m or €	26m	≥3
Coordination action (CA)**		€1.5m		≥3
Support action (SA)**	€0.	5m	≥:	1
* for CP-IPs there is also a lower lir	nit to t	he requ	lested E	C grant: €6m
** for CAs and CAs there are served	and the second			and the state

** for CAs and SAs there are some exceptions to the upper limit.

<u>Warning</u>: the limits for minimum and maximum requested EC grant

and for the minimum number of partners are **eligibility** criteria !





FP7 HD&A portfolio

Large collaborative projects:

·MARK-AGE: European study to establish biomarkers of Human ageing (01.04.2008, 11.9 MIO€)

•TOLERAGE: Normalisation of immune reactivity in old age – from basic mechanisms to clinical application (01.04.2008, 7.7MIO€)

•RESOLVE: Resolve chronic inflammation and achieve healthy ageing by undersatnding non-regenerative repair (01.04.2008, 10.6MIO€)

Co-ordination and support actions:

 WHY WE AGE: A road map for European research on molecular aspects of healthy ageing (01.01.2009, 0.49MIO€)
 PREDICT: Increasing the participation of elderly in clinical trials (01.02.2008, 0.75MIO€)



Other ageing-related 1st call contracts

Visual impairment and degeneration: A road-map for vision research within Europe (EUROVISIONNET)

Research area: HEALTH-2007-2.4.5-9

Assessment of hearing in the elderly: aging and degeneration: integration through immediate intervention (AHEAD III)

Research area: HEALTH-2007-2.4.5-7

• Genetic factors for osteoporosis (GEFOS)

Research area: HEALTH-2007-2.4.5-4 Genetic factors of Osteoporosis



IMI, the Innovative Medicine Initiative, http://www.imi-europe.org/Pages/de ERA-AGE, the European Research Area Network, http://eraage.group.shef.ac.uk/ AAL, Ambient Assisted Living http:// www.aal-europe.eu/

ERC, the European Research Council, http://erc.europa.eu/





Contacts & Information

Website FP7 Health : http://cordis.europa.eu/fp7/heal Experts registration: https://cordis.europa.eu/emmfp7

Database of FP6 projects: www.lifecompetence.eu

National contact points: http://cordis.europa.eu/fp7/health/support_en.htm

Infodays @ home: check the website!

Human development and ageing in Health: Beatrice. Lucaroni@ec.euopa.eu

Joint Programming: Etienne Magnien, Head of Unit DGRTDB1





The Health

Director – Dr. Ruxandra Dainectorate

Medical and Public Health Research unit (F2)

Head of Unit: Dr. Manuel Hallen (manuel.hallen@ec.europa.eu) Deputy: Dr. Maria Vidal (maria-jose.vidal-ragout@ec.europa.eu) Head of sector Public Health: K. McCarthy (kevin.mccarthy@ec.europa.eu)

Infectious Diseases unit (F3)

Head of unit: Dr. Alain Vanvossel (alain.vanvossel@ec.europa.eu) Deputy: Dr. Anna Lönnroth (anna.lonnroth@ec.europa.eu) Head of IMI sector: Dr. Irene Norstedt (irene.norstedt@ec.europa.eu)

Genomics and Systems Biology unit (F4)

Head of unit: Patrik Kolar (patrik.kolar@ec.europa.eu) Deputy: Dr. B. Mulligan (bernard.mulligan@ec.europa.eu) Health Biotechnology unit (F5)

Head of unit: Dr. Arnd Hoeveler (arnd hoeveler@ec.europa.eu)Coordination unit (F1)Admin. & Finance unitHead of unit: Stéphane(F6)HoganHead of unit: Giorgios



Joint Programming in Research

COOPERATION

Response to challenges: Joint programming

(Commission Communication on Joint Programming, July 2008 and Council Conclusions adopted in December 2008)

Definition:

Member States engaging **voluntary** and on the basis of **variable geometry**

... in the definition, development and implementation of **common strategic research agendas**

... based on a **common vision** on how to address **major societal challenges**



Joint Programming in Research, cont'd

What Joint Programming is not:

- asking for more power to the Commission
- a new instrument for Community research
- Community funding a priori

Not all research co-operation is Joint Programming

Criteria for identifying the right themes :

- Effective commitment of Member States
- The theme is focussed and addresses a European/global challenge
- Clear and realistic objectives can be set
- Clear added value to existing situation in research financing
- Relevant stakeholders have been involved
- Potential of generating benefits for European citizens/
 -competitiveness and of increasing efficiency and





The Alzheimer pilot Joint Programming Initiative - State of Play

A declaration of intent and commitment of participating MS A <u>focused theme</u> that addresses a major European Health challenge A list of clear and <u>realistic scientific, medical and social objectives</u> A willingness to coordinate similar programmes toward transnational <u>European added value</u> while not undermining existing opportunities and avoiding unnecessary duplications among national programmes An <u>involvement of scientists and physicians</u> for bottom-up European projects from the beginning to the end A new initiative addition research to the highest benefit of European population and economy









